If the purpose of medicine is not just to treat disaster but to spot it before it starts rearranging the furniture, what do we call it when a lifesaving test exists and most of the people who need it still never get through the door?
That is the uncomfortable little existential burr inside a new 2026 study on lung cancer screening in the United States. Lung cancer screening is not glamorous. It does not arrive wearing a biotech cape. It is a low-dose CT scan - basically a quieter, lower-radiation look inside the chest for people at high risk, mostly current or former heavy smokers. Yet when it works, it can catch cancer before symptoms crash the party.
The new study by Burus and colleagues looked at 2024 national survey data and found that about 24.5% of eligible adults were up to date on screening - roughly 1 in 4. That is better than 2022, with a 6 percentage point increase, but let’s be honest: if your smoke alarm worked only one-quarter of the time, you would not call that a victory lap. You would call an electrician and maybe say a few words not fit for a family oncology blog. (Burus et al., 2026)
The Scan Is Not the Hard Part
Picture the screening process as a subway map. The scan itself is one station. Getting there is the whole chaotic transit system: knowing you qualify, having insurance, having a clinician bring it up, surviving the shared decision-making conversation, finding a screening center, getting time off work, arranging transportation, and then coming back again next year because this is an annual thing, not a one-and-done oil change.
That helps explain why the numbers in this paper are both encouraging and mildly maddening.
The study found huge variation across the country. Massachusetts was at 38.36%, while South Dakota sat at 13.43%. No state had a significant decline since 2022, which is good. But the map still looks less like a coordinated public health effort and more like someone spilled screening access across the Northeast and hoped for the best.
The gaps within populations are just as revealing. Screening in 2024 was especially low among uninsured eligible adults, at 6.07%. Meanwhile, people with military-related insurance reached 39.05%. That contrast is not subtle. It suggests that when systems build organized programs, reminders, navigation, and follow-through, people actually get screened. Shocking, I know - humans respond well when the maze has fewer dead ends.
Where the Progress Stalls Out
Here is the part that should make everybody sit up a little straighter.
Burus and colleagues found that improvements were uneven, with no significant change among Hispanic, non-Hispanic Asian, or non-Hispanic Black adults between 2022 and 2024. So yes, the national average rose. But averages are sneaky little magicians. They wave one hand, show you progress, and hope you do not notice who got left standing on the platform.
That pattern fits with other recent work. A 2024 commentary in JAMA Network Open argued that lung cancer screening inequities need direct attention, not hand-waving about awareness alone (Carter-Bawa, 2024). Another 2024 qualitative study found that screening decisions are shaped by environmental and psychosocial factors like mistrust, clinician communication, and everyday life logistics - because, inconveniently, people are not spreadsheets (Richmond et al., 2024).
Why This Paper Matters
The biggest misconception about lung cancer screening is that the science problem was the scan. It wasn’t only the scan. We already had strong evidence behind annual low-dose CT screening for high-risk adults, and the USPSTF broadened recommendations in 2021 to include adults 50 to 80 years old with a 20 pack-year smoking history who currently smoke or quit within the past 15 years (Krist et al., 2021).
The real challenge is implementation. Or, in plain English, getting real people into real scanners in real zip codes.
A 2024 study of 2022 data found similarly low screening uptake, so this new paper gives us something valuable: proof that movement is possible, but also proof that momentum alone does not fix inequity (Bandi et al., 2024). Reviews of the field make the same point from a wider angle. The technology is solid, the promise is real, and the bottlenecks are increasingly about access, logistics, follow-up, and trust (Li et al., 2022).
If these gains keep growing - and if they grow more evenly - the real-world impact could be enormous. Earlier detection usually means more cancers found when they are still localized and more treatable. That is not just a nicer chart. That is more people getting a diagnosis before the disease turns the whole neighborhood upside down.
This paper is a reminder that screening is not just a machine in a radiology suite. It is a system. And systems, unlike tumors, can actually be redesigned.
References
- Burus T, McAfee CR, Knight JR, Mullett TW, Hull PC. Lung Cancer Screening Prevalence and Changes in 2024. JAMA Internal Medicine. Published online April 27, 2026. DOI: 10.1001/jamainternmed.2026.0493
- Bandi P, Star J, Ashad-Bishop K, Kratzer T, Smith R, Jemal A. Lung Cancer Screening in the US, 2022. JAMA Internal Medicine. 2024;184(8):882-891. DOI: 10.1001/jamainternmed.2024.1655
- Krist AH, Davidson KW, Mangione CM, et al. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(10):962-970. DOI: 10.1001/jama.2021.1117
- Li C, Wang H, Jiang Y, et al. Advances in lung cancer screening and early detection. Cancer Biology & Medicine. 2022;19(5):591-608. DOI: 10.20892/j.issn.2095-3941.2021.0690. PMCID: PMC9196057
- Carter-Bawa L. Shifting the Lens on Lung Cancer Screening Inequities. JAMA Network Open. 2024;7(5):e2412782. DOI: 10.1001/jamanetworkopen.2024.12782
- Richmond J, Fernandez JR, Bonnet K, et al. Patient Lung Cancer Screening Decisions and Environmental and Psychosocial Factors. JAMA Network Open. 2024;7(5):e2412880. DOI: 10.1001/jamanetworkopen.2024.12880
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.